Inactive Instrument

Intervacc AB (publ) Stock Nasdaq Stockholm

SE0009607252

Biotechnology & Medical Research

Valuation: Intervacc AB (publ)

Market Cap	331M 33.36M 29.28M 27.52M 25.16M 47.02M 3.2B 47.37M 128M 1.63B 125M 123M 5.28B	P/E 2026 *	-0.87x	P/E 2027 *	-0.87x
Enterprise Value	242M 24.38M 21.4M 20.11M 18.39M 34.36M 2.34B 34.62M 93.66M 1.19B 91.55M 89.54M 3.86B	EV / Sales 2026 *	11.5x	EV / Sales 2027 *	8.99x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Intervacc AB (publ)

08-20	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW
07-30	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
07-30	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
07-29	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
07-29	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
05-22	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
05-15	Sweden's Intervacc Elects New Chair	MT
05-15	Appoints Emil Billbäck as chairman	RE
05-13	Intervacc elects Emil Billbäck as chairperson of board	RE
05-13	Intervacc AB Announces Board Changes	CI
05-13	Intervacc Q1 net sales down at SEK 3.4 million	RE
05-13	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

More news

Analysts' recommendations: Intervacc AB (publ)

24-05-20	Penser reiterates motivated value for Intervacc - report met expectations	FW
24-02-21	Penser lowers Intervacc's motivated value	FW
23-11-17	Penser makes minor estimate adjustments in Intervacc	FW
23-05-04	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
23-02-20	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Press Releases: Intervacc AB (publ)

09-15	Intervacc to present at upcoming International Healthcare Conference	AQ
09-01	Intervacc: Highlights from DNB Carnegie’s Micro Cap Day	AQ
08-24	Intervacc (Q2 Review): Key catalysts nearing	AQ
08-21	Intervacc: In the right direction – Q2 review	AQ
08-20	Intervacc (Q2 initial take): Few surprises – all eyes on the label extension	AQ

More press releases

Managers and Directors: Intervacc AB (publ)

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	2026-02-04
Jan Persson DFI	Director of Finance/CFO	-	2020-02-05
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	2020-06-10

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	2026-05-12
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	2023-12-31
Björn Ingemar Odlander BRD	Director/Board Member	68	2024-12-31

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERVACC AB (PUBL)	-2.15%	-1.02%	-	-	33.36M
WUXI APPTEC CO., LTD.	+0.06%	+6.49%	+60.29%	+111.13%	74.18B
ARGENX SE	-0.17%	-3.87%	+34.15%	+74.85%	59.55B
INSMED INCORPORATED	-2.05%	-3.46%	-18.60%	+352.20%	25.84B
BIONTECH SE	-2.39%	+2.74%	+0.19%	-5.91%	24.73B
GENMAB A/S	-0.68%	+1.69%	+22.20%	-9.48%	20.87B
PHARMAESSENTIA CORPORATION	+1.29%	-2.49%	+152.11%	+333.06%	15.32B
EXELIXIS, INC.	-2.44%	-0.09%	+42.50%	+164.11%	14.06B
SUMMIT THERAPEUTICS INC.	-3.91%	-4.91%	-14.10%	+779.68%	13.12B
MADRIGAL PHARMACEUTICALS, INC.	-1.12%	-3.04%	+15.72%	+234.56%	11.85B
Average	-1.36%	-0.40%	+32.72%	+226.02%	28.84B
Weighted average by Cap.	-0.81%	+0.70%	+36.30%	+161.37%

	2026 *	2027 *
Net sales	21M 2.12M 1.86M 1.75M 1.6M 2.99M 203M 3.01M 8.14M 103M 7.96M 7.78M 336M	30M 3.03M 2.66M 2.5M 2.28M 4.27M 290M 4.3M 11.63M 148M 11.37M 11.12M 479M
Net income	-82.45M -8.32M -7.3M -6.86M -6.28M -11.73M -797M -11.81M -31.96M -406M -31.24M -30.56M -1.32B	-83.65M -8.44M -7.41M -6.96M -6.37M -11.9M -809M -11.99M -32.43M -412M -31.7M -31M -1.34B
Net Debt	-89M -8.98M -7.88M -7.41M -6.77M -12.66M -860M -12.75M -34.5M -439M -33.73M -32.99M -1.42B	-61M -6.16M -5.4M -5.08M -4.64M -8.68M -590M -8.74M -23.65M -301M -23.12M -22.61M -975M

Intervacc AB (publ) Stock Nasdaq Stockholm

Stocks

SE0009607252

Biotechnology & Medical Research

Valuation: Intervacc AB (publ)

Latest news: Intervacc AB (publ)

Analysts' recommendations: Intervacc AB (publ)

Press Releases: Intervacc AB (publ)

Quotes and Performance

Managers and Directors: Intervacc AB (publ)

Bio Therapeutic Drugs

Financials

Company Profile